ArticleBMC neuroscience2025
Dexmedetomidine pretreatment improves postsurgical delay in neurocognitive recovery in aged mice by inhibiting hippocampal microglial activation via activation of cholinergic anti-inflammatory pathways.
Article in BMC neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of preoperative warming combined with dexmedetomidine on postoperative delirium in elderly patients undergoing hip fracture surgery: a randomized controlled trial.Frontiers in medicine · 2026Trial
- Pharmacological interventions targeting the gut-brain axis in neurological disorders: mechanisms and translational applications.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPerioperative use of dexmedetomidine (DEX) reduces the incidence of Delayed Neurocognitive Recovery (DNR) in elderly patients, though mechanisms remain unclear. This study investigated whether DEX improves DNR by inhibiting microglial activation and explored the cholinergic anti-inflammatory pathway's role.
methodsAn exploratory laparotomy model was established in aged C57BL/6J mice, with preoperative treatment using DEX or DEX combined with α-bungarotoxin. Cognitive function was assessed through the novel object recognition (NOR) and Morris water maze (MWM) tests, while immunofluorescence was used to observe microglial morphology, and qPCR and ELISA were employed to detect inflammatory factor expression.
resultsDEX pretreatment significantly reduced the escape latency of aged mice on postoperative days 3-5 (50.50 ± 3.73 vs. 55.01 ± 4.01, P = 0.04; 36.36 ± 4.31 vs. 43.42 ± 5.64, P = 0.01; 27.00 ± 3.94 vs. 34.50 ± 5.54, P = 0.006), increased number of times crossing the previous platform location (2.50 ± 1.31 vs. 1.08 ± 0.90, P = 0.02), and percentage of dwell time in the target quadrant (37.87 ± 9.66 vs. 25.00 ± 4.48, P < 0.001). DEX pretreatment also reduced the expression of pro-inflammatory cytokines in the hippocampus (TNF-α, 604.10 ± 165.40 vs. 915.30 ± 97.64, P = 0.002; IL-6, 145.30 ± 12.11 vs. 176.50 ± 16.15, P = 0.002; IL-1β, 59.68 ± 4.29 vs. 68.73 ± 3.11, P = 0.001) of aged mice postoperatively, as well as in the spleen and serum. Additionally, DEX pretreatment reduces microglia count (96.60 ± 11.84 vs. 136.20 ± 32.62, P = 0.05), fluorescence (0.96 ± 0.06 vs. 1.10 ± 0.02, P < 0.001), morphology (7.20 ± 2.17 vs.12.80 ± 2.28, P = 0.002) in aged mice post-surgery. Pre-administration of α-bungarotoxin before DEX pretreatment partially reversed these effects.
conclusionsDEX pretreatment ameliorated DNR in aged mice is related to inhibition of microglial activation, which was at least partially attributed to activation of the cholinergic anti-inflammatory pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.